Payment overview · 2025
General Payments
$791.09
36 reported records · 13 companies
Healthcare provider profile · identity verified
David B Mishkin, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · FORT LAUDERDALE, FL · NPI 1700896206
Verified facts
What the public records show
CMS Open Payments records show David B Mishkin, D.O. received $791.09 in general payments during 2025 across 36 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $176.28 | 22.3% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $136.26 | 17.2% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $116.27 | 14.7% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $68.27 | 8.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $53.98 | 6.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.30 | 6.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $45.10 | 5.7% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.37 | 3.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $26.97 | 3.4% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $23.80 | 3.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.10 | 2.9% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $22.62 | 2.9% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $19.77 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $791.09 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $136.26 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $136.26 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $116.27 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $95.05 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $53.98 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.30 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $45.27 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.10 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $45.10 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $40.39 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $29.37 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $26.97 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.10 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 195 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 41 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
79 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
195 | 62 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 916 | 279 |
| Alprazolam | Alprazolam | 705 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 544 | 166 |
| Losartan Potassium | Losartan Potassium | 483 | 155 |
| Lisinopril | Lisinopril | 410 | 124 |
| Pantoprazole Sodium | Pantoprazole Sodium | 394 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 376 | 108 |
| Temazepam | Temazepam | 335 | 63 |
| Metformin Hcl | Metformin Hcl | 328 | 110 |
| Gabapentin | Gabapentin | 313 | 87 |
| Tamsulosin Hcl | Tamsulosin Hcl | 301 | 103 |
| Omeprazole | Omeprazole | 299 | 95 |
| Celecoxib | Celecoxib | 282 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 280 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 278 | 92 |
| Zolpidem Tartrate | Zolpidem Tartrate | 246 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 229 | 61 |
| Simvastatin | Simvastatin | 224 | 65 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 218 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 199 | 52 |
| Eliquis | Apixaban | 195 | 62 |
| Escitalopram Oxalate | Escitalopram Oxalate | 180 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 177 | 57 |
| Furosemide | Furosemide | 173 | 60 |
| Carvedilol | Carvedilol | 168 | 43 |
| Allopurinol | Allopurinol | 163 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 156 | 52 |
| Tizanidine Hcl | Tizanidine Hcl | 151 | 64 |
| Meloxicam | Meloxicam | 148 | 42 |
| Trazodone Hcl | Trazodone Hcl | 139 | 43 |
| Glipizide | Glipizide | 130 | 47 |
| Atenolol | Atenolol | 121 | 43 |
| Clonazepam | Clonazepam | 120 | 20 |
| Ibandronate Sodium | Ibandronate Sodium | 120 | 46 |
| Pregabalin | Pregabalin | 115 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 34 |
| Tramadol Hcl | Tramadol Hcl | 114 | 32 |
| Lorazepam | Lorazepam | 111 | 22 |
| Finasteride | Finasteride | 103 | 35 |
| Fenofibrate | Fenofibrate Nanocrystallized | 100 | 32 |
| Montelukast Sodium | Montelukast Sodium | 100 | 31 |
| Donepezil Hcl | Donepezil Hcl | 93 | 26 |
| Famotidine | Famotidine | 92 | 29 |
| Prednisone | Prednisone | 92 | 47 |
| Nifedipine Er | Nifedipine | 83 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 82 | 24 |
| Symbicort | Budesonide/Formoterol Fumarate | 79 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 78 | 56 |
| Propranolol Hcl | Propranolol Hcl | 76 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 75 | 23 |
| Potassium Chloride | Potassium Chloride | 73 | 28 |
| Alendronate Sodium | Alendronate Sodium | 71 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 19 |
| Diazepam | Diazepam | 70 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 70 | 25 |
| Spironolactone | Spironolactone | 70 | 22 |
| Sertraline Hcl | Sertraline Hcl | 69 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 20 |
| Ibuprofen | Ibuprofen | 60 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 59 | 19 |
| Bumetanide | Bumetanide | 57 | 19 |
| Ezetimibe | Ezetimibe | 55 | 19 |
| Valsartan | Valsartan | 55 | 21 |
| Clonidine Hcl | Clonidine Hcl | 52 | 17 |
| Fenofibrate | Fenofibrate | 52 | 21 |
| Bupropion Xl | Bupropion Hcl | 51 | 17 |
| Chlorthalidone | Chlorthalidone | 51 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 48 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 26 |
| Glimepiride | Glimepiride | 47 | 13 |
| Cephalexin | Cephalexin | 45 | 34 |
| Testosterone Cypionate | Testosterone Cypionate | 45 | 17 |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | 13 |
| Mirtazapine | Mirtazapine | 41 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 41 | 17 |
| Terazosin Hcl | Terazosin Hcl | 40 | suppressed |
| Azithromycin | Azithromycin | 39 | 39 |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Ondansetron Odt | Ondansetron | 38 | 11 |
| Naproxen | Naproxen | 37 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 37 | suppressed |
| Glipizide Er | Glipizide | 34 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | 12 |
| Lovastatin | Lovastatin | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | 11 |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 29 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | 13 |
| Valacyclovir | Valacyclovir Hcl | 29 | 14 |
| Xarelto | Rivaroxaban | 28 | 11 |
| Methotrexate | Methotrexate Sodium | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | 11 |
| Jardiance | Empagliflozin | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 14 |
| Ramipril | Ramipril | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Anastrozole | Anastrozole | 21 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 18 |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 11 |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Eligard | Leuprolide Acetate | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Prolia | Denosumab | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Qulipta | Atogepant | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Digoxin | Digoxin | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $791.09 · 36 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APRETUDE, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, GEMTESA, Leqembi, MOUNJARO, NP Thyroid 60, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, TRELEGY ELLIPTA, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error